US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.18

-0.0400-3.28%

Post-market: 1.17-0.0100-0.85%19:43 EDT

Volume:246.99K

Turnover:301.61K

Market Cap:19.84M

PE:-2.32

High:1.25

Open:1.24

Low:1.17

Close:1.22

Loading ...

Overview Company News Filings

BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing

Mira Pharmaceuticals Inc - on April 30, Agreed to Acquire Skny Pharmaceuticals - SEC Filing

THOMSON REUTERS

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million

Mira Pharmaceuticals: Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

THOMSON REUTERS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive

Psychedelic: Clearmind completes clinical site initiations for AUD trial

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

ACCESS Newswire

Top Midday Gainers

MT Newswires Live

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

ACCESS Newswire

BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2

Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing

THOMSON REUTERS

Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025

THOMSON REUTERS

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA Continues Positive Testing Run

Zacks Small Cap Research

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2

BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing

Mira Pharmaceuticals Inc - First Human Efficacy Data Expected in H1 2026

THOMSON REUTERS

Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing

THOMSON REUTERS

Miramar's shareholders block $401 million deal to buy Henderson Land's unit

Chains of War ($MIRA) Shows Remarkable Growth Trajectory with a 1-Month Surge of 2965.37%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MIRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.18,"timestamp":1747166400000,"preClose":1.22,"halted":0,"volume":246986,"hourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.18,"latestTime":"19:43 EDT","volume":394,"amount":462.4566,"timestamp":1747179825696},"delay":0,"floatShares":13174336,"shares":16813654,"eps":-0.508455,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"05-13 16:00:00 EDT","open":1.24,"high":1.25,"low":1.17,"amount":301613.02975560003,"amplitude":0.065574,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.508455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747209600000},"marketStatusCode":0,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.22,"preHourTrading":{"tag":"盘前","latestPrice":1.1701,"preClose":1.22,"latestTime":"09:00 EDT","volume":1454,"amount":1725.2019701999998,"timestamp":1747141246220},"postHourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.18,"latestTime":"19:43 EDT","volume":394,"amount":462.4566,"timestamp":1747179825696},"volumeRatio":0.135131},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":13174336,"roa":"-127.59%","roe":"-238.90%","lyrEps":-0.508455,"volumeRatio":0.135131,"shares":16813654,"dividePrice":0,"high":1.25,"amplitude":0.065574,"preClose":1.22,"low":1.17,"week52Low":0.51,"pbRate":"9.02","week52High":5.01,"institutionHeld":0,"latestPrice":1.18,"eps":-0.508455,"divideRate":0,"volume":246986,"delay":0,"ttmEps":-0.508455,"open":1.24,"prevYearClose":1.14,"prevWeekClose":1.22,"prevMonthClose":1.16,"prevQuarterClose":0.98,"fiveDayClose":1.2,"twentyDayClose":0.89,"sixtyDayClose":1.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533813601","title":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533813601","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533813601?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:51","pubTimestamp":1746705100,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC FilingMay 8  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ON APRIL 30, AGREED TO ACQUIRE SKNY PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - COMBINED ENTERPRISE VALUE EXCEEDS $60 MILLION - SEC FILINGMIRA PHARMACEUTICALS INC -UNDER DEAL SKNY TO CONTRIBUTE $5 MILLION TO MIRA AT CLOSING - SEC FILINGSource text: [ID:n0001641172-25-009155]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533418621","title":"Mira Pharmaceuticals Inc - on April 30, Agreed to Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533418621","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533418621?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:40","pubTimestamp":1746704423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533181211","title":"MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533181211","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533181211?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:31","pubTimestamp":1746703907,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced a definitive agreement to acquire SKNY Pharmaceuticals Inc., a biotechnology company specializing in therapies for obesity and nicotine dependence. The acquisition, unanimously approved by Mira's Board of Directors, follows independent valuations by Moore Financial Consulting, which valued SKNY at approximately $30.5 million and Mira at $30 million. As part of the transaction, SKNY will contribute $5 million in assets or cash to Mira upon closing. This strategic move is expected to bolster Mira's balance sheet and enhance its development initiatives, creating a combined enterprise with a value exceeding $60 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL1bmqqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533845126","title":"Mira Pharmaceuticals: Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2533845126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533845126?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:34","pubTimestamp":1746531284,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2530468901","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2530468901","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530468901?lang=en_us&edition=fundamental","pubTime":"2025-04-28 03:31","pubTimestamp":1745782287,"startTime":"0","endTime":"0","summary":"Tilray announced plans to exit New Zealand medical cannabis market to focus on Australia. Village Farms was granted 180-day extension to regain Nasdaq listing requirements. SNDL launched “Rise Rewards” loyalty program to boost customer experience. Simply Solventless celebrated profitability at Humble Grow Co., surpassing projections. Cybin expanded clinical partnerships to accelerate phase 3 trial evaluating CYB003 for depression treatment. Compass Pathways completed dosing in phase 3 trial of COMP360 for treatment-resistant depression. Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.The New Zealand medical cannabis sector has faced challenges, particularly high regulato","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-193127070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","ACB","VFF","SQQQ","TLRY",".IXIC","MNQmain","BK4007","USAW.SI","BK4547","SNDL","BK4596","NVIW.SI","NQmain","BK4139","PSQ","BK4557","NZ20C.NZ","QID","NZ50G.NZ","CYBN","TQQQ","T10G.NZ","QLD","BK4189","MIRA","CMPS","USJW.SI"],"gpt_icon":1},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","SEEL","BK4202","BK4539","NUMIF","SILO","SNPX","ENVB","IXHL","AGNPF","BK4139","NRXP","DRUG","MDXXF","ALID","PHRRF","BETRF","KTTA","RLMD","BK4007","GHRS","ENTBF","FLHLF","BK4168","CMND","PBM","BK4547","QNTM","SPRC","CMPS","ATAI","OPTHF","CYBN","RVVTF","MNMD","PSYGF","MYCOF"],"gpt_icon":0},{"id":"2529504063","title":"MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504063","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504063?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. , or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced the completion of in vitro release testing  for its topical formulation of Ketamir-2. The formulation is under investigation for localized application in pain-related conditions.\"As we continue expanding the Ketamir-2 program, we remain committed to building long-term shareholder value through strategic innovation and disciplined execution,\" said Erez Aminov, Chairman and CEO of MIRA. \"The ability to develop both oral and a localized topical formulation positions us to address a much broader segment of the pain market, which represents a significant commercial opportunity and a clear path for differentiation in a space that urgently needs safer, more targeted treatment options.\". MIRA is currently advancing preclinical studies to evaluate the topical formu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-reports-positive-vitro-120000673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B5TLWC47.USD","BK4007","BK4104","FAST","BK4588","BK4585","IE00BFXG0V08.USD","MIRA","IE00BYQQ9H92.USD","BK4567"],"gpt_icon":1},{"id":"2528275805","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528275805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528275805?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:05","pubTimestamp":1744826711,"startTime":"0","endTime":"0","summary":"RadNet  has agreed to acquire iCad  in an all-stock deal valued at roughly $103 million, they said late Tuesday.Shares of iCad soared 71%, with intraday trading volume of over 17.2 million from a daily average of about 508,000.Treasure Global  struck a partnership with Mezzofy , securing distribution rights for Mezzofy's digital coupon platform in Malaysia. It expects to generate $2 million to $4 million in annual revenue in the first 12 months of the rollout.Shares surged 57% as intraday trading volume soared to more than 92 million from a daily average of about 354,000.Mira Pharmaceuticals  said Wednesday that data demonstrated the potential efficacy of its oral ketamine analog, Ketamir-2, in treating diabetic neuropathy in an animal model.Shares advanced 15%, with intraday trading volume rising to over 44.8 million from a daily average of about 255,000.Price: 50.78, Change: -2.30, Percent Change: -4.33","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4167","BK4007","LU2065731478.USD","MIRA","ICAD","BK4009","TGL","RDNT","BK4196"],"gpt_icon":1},{"id":"2527221611","title":"MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527221611","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527221611?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:00","pubTimestamp":1744804800,"startTime":"0","endTime":"0","summary":"Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal. MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. , or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy.In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin . This resulted in hyperglycemia and neuropathic symptoms, including hyperalgesia and allodynia, mimicking human diabetic pathology. By week 8, most diabetic rats exhibited sensory hypersensitivity. Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity. \"Millions of patients with dia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-positive-results-120000582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2552382058.USD","BK4585","LU2552382215.SGD","STZ","LU2552382132.HKD","BK4169","BK4007","BK4559","MIRA","BK4504","BK4588"],"gpt_icon":0},{"id":"2527290559","title":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290559","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290559?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:35","pubTimestamp":1744803308,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2April 16  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ANNOUNCES POSITIVE STUDY RESULTS FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - KETAMIR-2 SHOWS SIGNIFICANT REDUCTION IN NEUROPATHIC PAIN SYMPTOMS - SEC FILINGMIRA PHARMACEUTICALS INC - TO INITIATE PHASE IIA TRIAL IN DIABETIC NEUROPATHY PATIENTS BY END OF 2025Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527977472","title":"Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977472?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:31","pubTimestamp":1744803111,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527829088","title":"Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527829088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527829088?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:31","pubTimestamp":1744803111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527297583","title":"EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527297583","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527297583?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:15","pubTimestamp":1744802158,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc.  on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy,a type of nerve damage that can occur in diabetes patients.In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin .Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity.Also Read: EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate. MIRA anticipates initiating its Phase 2a trial in diabetic neuropathy by the end of 2025, with the first human efficacy data expected in the first half of 2026.In addition, MIRA is actively conducting ongoing studies assessing the efficacy of Ketamir-2 in models of post-traumatic stress disorder.The transaction includes a $5 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-ketamir-2-111558635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4007","LU2552382058.USD","STZ","BK4585","LU2552382215.SGD","BK4169","BK4559","MIRA","LU2552382132.HKD","BK4588"],"gpt_icon":0},{"id":"2527622534","title":"MIRA Continues Positive Testing Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2527622534","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527622534?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:05","pubTimestamp":1744801500,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just announced more positive testing results that build on all of the other positive results seen to this point.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-positive-testing-run-110500207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4007","LU2552382058.USD","STZ","BK4585","LU2552382215.SGD","BK4169","BK4559","MIRA","LU2552382132.HKD","BK4588"],"gpt_icon":0},{"id":"2524163461","title":"Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2524163461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524163461?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:37","pubTimestamp":1743511058,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced the enrollment of the first subjects in its Phase 1 clinical trial of Ketamir-2, a novel oral ketamine analog...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-enrolls-first-subjects-in-phase-1-trial-of-ketamir-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-enrolls-first-subjects-in-phase-1-trial-of-ketamir-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2524197593","title":"BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197593","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197593?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:33","pubTimestamp":1743507209,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC FilingApril 1  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ENROLLS FIRST SUBJECTS IN PHASE 1 TRIAL FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - PHASE 1 STUDY EXPECTED TO COMPLETE BY Q4 2025 - SEC FILINGMIRA PHARMACEUTICALS INC - FIRST HUMAN EFFICACY DATA EXPECTED IN H1 2026Source text: [ID:n0001641172-25-001987]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":1},{"id":"2524197337","title":"Mira Pharmaceuticals Inc - First Human Efficacy Data Expected in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197337?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:32","pubTimestamp":1743507124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2524197336","title":"Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197336?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:32","pubTimestamp":1743507124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF02L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2523594854","title":"Miramar's shareholders block $401 million deal to buy Henderson Land's unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594854","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594854?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:33","pubTimestamp":1743420788,"startTime":"0","endTime":"0","summary":"UPDATE 1-Miramar's shareholders block $401 million deal to buy Henderson Land's unitUpdates with details and background from paragraph 2 onwardsMarch 31  - Miramar Hotel and Investment's 0071.HK shareholders rejected the HK$3.12 billion  deal under which it was buying a property from Hong Kong's Henderson Land Development 0012.HK for building a hotel and commercial complex.Over 53% of stockholders voted against the proposed deal, while around 46% supported the transaction, an exchange filing by the hotel operator showed on Monday.Henderson Land and Miramar, in January, unveiled plans to change ownership of the property, with the former scrapping plans for a new commercial tower.Miramar intended to develop a hotel to ease pressure on its popular hotel, The Mira Hong Kong. The property's sale, located at the heart of Hong Kong's Tsim Sha Tsui district, was seen as a major sign of a post-pandemic recovery in the local tourism industry.Henderson Land, which owns just over half of Miramar, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE0L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1559","BK4007","BK1240","00071","BK1164","00012","BK1601","MIRA"],"gpt_icon":0},{"id":"2523463979","title":"Chains of War ($MIRA) Shows Remarkable Growth Trajectory with a 1-Month Surge of 2965.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523463979","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523463979?lang=en_us&edition=fundamental","pubTime":"2025-03-29 05:54","pubTimestamp":1743198868,"startTime":"0","endTime":"0","summary":"Chains of War ($MIRA) has recently recorded remarkable growth. As per the latest data, Chains of War ($MIRA) went through a 2965.37% increase over the past month. This has gained the attention of the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67e71a92e283516da47e59ba/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","MIRA"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-05-12","current":-2.612193,"percent":0.232057,"low":-15.501022,"twenty":-3.083741,"median":-1.921032,"eighty":-1.335972,"high":-0.648567,"avg":-3.300606,"sd":3.545667,"marketCap":20512657},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-12","current":-2.612193,"twenty":-3.083741,"median":-1.921032,"eighty":-1.335972,"marketCap":20512657}],"updateTime":1747197394020}}}